Based on the study of CFS samples from a large cohort of PD patients at different stages, as well as healthy and diseased controls, the authors proposed a combination of alpha-synuclein, DJ-1 protein, total tau protein, phosphorylated tau protein, beta-amyloid peptide l-42, Fit3 ligand, and microglial inflammatory mediator fractalkine, as diagnostic markers not just for PD diagnosis but for differentiation from MSA patients, and correlation with disease severity and progression [96]. The gene discussed is MAPT; the disease is Parkinson disease.